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ing new angle to transposon regulation. 
The relatively low TnsE binding affinity for 
the β clamp suggests that it has evolved to 
use the replication factor but not to appro-
priate it entirely at the expense of other β 
clamp binding partners and functions. In 
the wake of the new findings of Parks et al., 
it is now important to determine how such 
interactions between transposon proteins 
and the replication machinery occur, how 
they are temporally integrated into DNA 
replication and other processes coordi-
nated by the β clamp, and whether other 
host proteins are also required.
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During metastasis, migrating breast cancer stem cells undergo a loss of polarity leading to an 
epithelial-to-mesenchymal transition (EMT). Gupta et al. (2009) use this attribute of cancer stem 
cells to develop a high-throughput screen, which successfully identifies small molecules that 
specifically inhibit cancer stem cell proliferation through the induction of differentiation.Although tumor metastases are the cause 
of death in more than 80% of human can-
cer patients, the molecular mechanisms 
underpinning metastasis are still poorly 
understood. However, one theme that has 
emerged from recent work is that metas-
tasis involves defects in the molecular 
machines responsible for epithelial polar-
ity and hence for the epithelial-to-mes-
enchymal transition (EMT) (Kalluri and 
Weinberg, 2009). Epithelial cell polarity is 
established by multiple cellular processes, 
including polarized trafficking of cytoskel-
etal and plasma membrane proteins, the 
maintenance of a diffusion barrier (tight 
junctions) (Humbert et al., 2008), and a 
3D organization machinery that integrates 
extracellular information from receptors, 
adhesion proteins, and neighboring cells 
(Tanos and Rodriguez-Boulan, 2008). 
Hence, the loss of epithelial polarity during EMT can result from altered regulation of 
many different signaling pathways, tran-
scription factors, chromatin regulators, 
and proteins involved in cell adhesion and 
polarity (Kalluri and Weinberg, 2009; Tanos 
and Rodriguez-Boulan, 2008). Indeed, the 
list of oncogenes and tumor suppressors 
that modulate cell polarity is long and 
growing (Humbert et al., 2008; Tanos and 
Rodriguez-Boulan, 2008). In recent work, 
it has been shown that epithelial stem cells 
may undergo EMT and that EMT induction 
endows epithelial cells with salient fea-
tures of stem cells. These cells can also 
exhibit properties of cancer stem cells 
upon overexpression of oncogenic Ras 
(Mani et al., 2008). In their current work, 
published in this issue of Cell, Gupta et al. 
(2009) use these newly discovered attri-
butes of mammary epithelial cells (that is, 
induction of EMT and stem cell features by Cell 13defined genetic alterations) to establish a 
high-throughput screen for compounds 
that selectively target cancer stem cells.
Gupta et al. use telomerase-immortal-
ized human mammary epithelial (HMLE) 
cells, in which knockdown of E-cadherin 
by RNA interference promotes EMT and 
the acquisition of features typical of can-
cer stem cells, including high levels of 
CD44, low levels of CD24, and the capac-
ity to form mammospheres (Figure 1). 
Cells depleted of E-cadherin also show 
increased resistance to several estab-
lished tumor chemotherapeutics. In this 
respect, they resemble human breast 
carcinoma stem cells that contribute to 
tumor relapse in vivo. Gupta et al. estab-
lish that these cells are ideally suited for a 
high-throughput, cellular screen for com-
pounds that selectively eliminate cancer 
stem cells (Figure 1). The most extensively 8, August 21, 2009 ©2009 Elsevier Inc. 623
figure 1. salinomycin Targets Breast cancer stem cells
Depicted is the screening approach used by Gupta et al. (2009). Control human mammary epithelial (HMLE) cells express the basolateral marker E-cadherin 
and high levels of CD24. These cells do not form mammospheres in suspension culture. In contrast, HMLE cells treated with a short hairpin RNA targeting E-
cadherin undergo changes consistent with an epithelial to mesenchymal transition (EMT), including upregulation of the mesenchymal marker vimentin. These 
cells exhibit features of cancer stem cells, including high levels of CD44 expression and the ability to form mammospheres in suspension culture. These two 
cell types were then subjected to a high-throughput chemical screen measuring cell viability, which led to the identification of salinomycin as a compound that 
targets breast cancer stem cells selectively.validated hit from their screen is salino-
mycin, a highly selective potassium iono-
phore, facilitating bidirectional ion flux 
(Mitani et al., 1975). Salinomycin selectively 
impairs the viability of cells with features 
of cancer stem cells. In artificial mixtures 
of Ras-transformed HMLE cells in which 
some cells exhibit EMT and cancer stem 
cell features and some cells do not, sal-
inomycin selectively eradicates cells with 
cancer stem cell properties. In contrast, 
established cancer chemotherapeutics 
(such as paclitaxel) have the opposite 
effect, even leading to cancer stem cell 
enrichment. In addition, in an orthotopic 
mouse model of lung metastasis using 
4T1 murine carcinoma cells, salinomycin 
fully reverses the partial EMT-phenotype 
of these cells in that they adopt an epithe-
lial phenotype. Although the mechanism 
of action for salinomycin is not yet clear, 
it appears that it might induce terminal 
epithelial differentiation accompanied by 
cell-cycle arrest rather than trigger cyto-
toxicity. This is consistent with evidence 
showing that salinomycin does not block 
proliferation in several other human mam-
mary carcinoma cell lines.
Importantly, salinomycin also eradi-
cates cells with cancer stem cell proper-
ties in mice. Tumors derived from 4T1 cells 
(or from Ras-transformed HMLE cells) 624 Cell 138, August 21, 2009 ©2009 Elsevieform less efficiently in mice after treat-
ment of the cells with salinomycin. Inter-
estingly, in mice inoculated with SUM159 
human breast cancer cells, treatment with 
salinomycin or paclitaxel delays tumor 
formation by 14 days. Furthermore, sal-
inomycin induces expression of plasma 
membrane-E-cadherin in these tumors, 
providing further evidence that salinomy-
cin might eliminate cancer stem cells by 
inducing their differentiation. Significantly, 
salinomycin also suppresses the metasta-
sis of 4T1 cells to the lung. This differs from 
paclitaxel, which increases the prevalence 
of lung metastases in this model. Thus, 
salinomycin might selectively suppress 
metastasis by inducing differentiation in 
the migrating cancer stem cells that have 
undergone EMT.
The authors employ then global 
expression profiling to show that the 
fraction of Ras-transformed HMLE cells 
with properties of cancer stem cells have 
a gene expression signature found in 
natural mammary stem cells and in can-
cer stem cells from human tumors. They 
compared three cell states: (1) paclitaxel 
treatment versus salinomycin treatment 
of Ras-transformed HMLE cells, (2) mam-
mospheres versus differentiation cultures 
of primary human mammary epithelial 
cells, and (3) cells expressing high levels r Inc.of CD44 versus those expressing high 
levels of CD24 as sorted from normal 
human mammary glands and mammary 
carcinomas. They report 25 genes that 
are upregulated and 14 that are down-
regulated consistently in all of the above 
comparisons. This analysis clearly estab-
lishes that the Ras-transformed HMLE 
cells eliminated by salinomycin have a 
gene expression signature characteristic 
of mammary and cancer stem cells.
Established breast cancer therapies 
often fail to achieve long-term patient 
survival, possibly because of tumor 
relapse as a result of chemotherapy-
resistant mammary cancer stem cells. 
Thus, new therapeutic strategies to spe-
cifically target these cancer stem cells 
are urgently required. Gupta et al. (2009) 
significantly advance this field by pre-
senting the first clear proof of principle 
that it is feasible to screen for drugs that 
specifically target breast cancer stem 
cells. The approach they chose evolved 
from the concept that normal mammary 
gland stem cells and cancer stem cells 
display a highly plastic epithelial phe-
notype, which allows them to undergo 
EMT in cell culture (Mani et al., 2008). 
It remains unclear, however, by which 
mechanisms salinomycin selectively 
targets cells after EMT. Salinomycin is 
used as an antibiotic against eukaryotic 
parasites in animals and inhibits carti-
lage degradation during bone develop-
ment (Peters et al., 2002). Given that it is 
a highly selective potassium ionophore, 
salinomycin may interfere with the func-
tion of potassium channels in cancer stem 
cells. It has been shown that tumor cells 
express elevated levels of various types 
of K+ channels. Their overexpression 
enhances proliferation, and drugs acting 
as channel blockers inhibit cell prolifera-
tion (Le Guennec et al., 2007; Zhang et 
al., 2009). Perhaps more importantly, 
certain K+ channels regulate migration. In 
a similar vein, certain G protein-coupled 
K+ channels are overexpressed in breast 
cancer lymph node metastases (Zhang In plants, the juvenile and adult phases 
of vegetative development can be dis-
tinguished by leaf morphology, and the 
reproductive phase of development can 
be distinguished by the production of 
flowers. SQUAMOSA PROMOTER BIND-
ING-LIKE (SPL) transcription factors are 
regulated by the microRNA miR-156 and 
influence the transitions between these 
developmental phases (Schwab et al., 
2005; Wu and Poethig, 2006). Intricate 
models have been proposed to explain 
the regulation of the developmental 
transitions between these phases, par-
ticularly between the adult vegetative 
and reproductive phases (Baurle and 
Dean, 2006). However, SPL transcription 
factors are often excluded from these 
models because their extreme genetic 
redundancy and the complexity of their 
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adult and from the vegetative to 
al., 2009; Wu et al., 2009) and De
and their transcription factor target al., 2009). Given the importance of the 
cell polarity machinery to cell migration 
(Etienne-Manneville, 2008), it is tempting 
to speculate that K+ channels targeted 
by salinomycin have a critical function in 
epithelial polarity and metastasis, which 
can be deregulated by salinomycin.
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regulation by microRNAs have made it 
difficult to pinpoint their exact functions 
in development. Wang et al. (2009) and 
Wu et al. (2009), reporting in this issue 
of Cell, and Yamaguchi et al. (2009), 
reporting in a recent issue of Develop-
mental Cell, now use a variety of elegant 
approaches to demonstrate precise 
functions for SPL transcription factors 
and their regulation by microRNAs at dif-
ferent stages of plant development.
The involvement of SPL transcription 
factors in the vegetative phase transition 
first became clear by studying miR-156, 
a microRNA whose overexpression pro-
longs the juvenile phase in both maize 
and the model plant Arabidopsis thali-
ana (Wu and Poethig, 2006; Chuck et al., 
2007). The miR-156 microRNA represses 
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tion factors in Arabidopsis, suggesting 
that some or all of these proteins pro-
mote the transition from the juvenile to 
the adult phase. In both Arabidopsis and 
maize, miR-156 expression decreases as 
the plant ages. Therefore, miR-156 likely 
acts during the juvenile phase to repress 
SPL transcription factors and delay the 
transition to the adult phase; increasing 
the abundance of SPL transcription fac-
tors shortens the juvenile phase and pro-
motes flowering (Wu and Poethig, 2006). 
Strikingly, the microRNA miR-172 shows 
a complementary pattern of expression, 
that is, low during the juvenile phase and 
high during the adult phase. In Arabidop-
sis, miR-172 represses expression of six 
members of the APETALA2 (AP2)-like 
family of transcription factors. Two of 
these transcription factors—TARGET OF 
 sPLash
ase transitions, from juvenile to 
ndings reported in Cell (Wang et 
l., 2009) reveal how microRNAs 
itions.
